| Dear John,
Welcome to Cancer Research UK's monthly newsletter – your guide to the latest research news, events and funding schemes from us and our partners.
We’ve officially launched our new strategy to support research for children’s and young people’s cancer. Over the next few years we’ll be focusing on building research capacity nationwide and fostering a coordinated research community to drive progress in this area. At this first stage, we’ve launched two new paediatric research funding calls, which are currently open for diverse applications. I encourage you to explore these schemes and share them with those who may be interested.
Read on to learn more about some exciting opportunities for multidisciplinary collaboration in the form of our joint conference with AACR and our Early Detection Innovation Sandpit, as well as some recent developments in CRUK’s commercialisation landscape.
Kind regards,
Iain Foulkes
Executive Director, Research & Innovation
Cancer Research UK |
|
|---|
|
|---|
|
|
| | | ESTABLISHED INDEPENDENT RESEARCHER, CLINICIAN, NON-CLINICAL RESEARCHERS |
|
|---|
|
|---|
| | | ESTABLISHED INDEPENDENT RESEARCHER, CLINICIAN |
|
|---|
|
|---|
| | | ESTABLISHED INDEPENDENT RESEARCHER, CLINICIAN |
|
|---|
|
|---|
|
|
EPS IN ONCOLOGY 2019: TIME RUNNING OUT TO REGISTER Delegate places are filling up fast for the CRUK–AACR Joint Conference on Engineering and Physical Sciences in Oncology in London this October. Join leading international scientists including Sangeeta Bhatia (MIT), Oliver Jonas (Harvard Medical School), Molly Stevens (Imperial College London) and Bern Pichler (University Hospital Tübingen). Discussions will cover cutting-edge topics including cancer research in the big data era and emerging technologies for cancer diagnosis. Avoid disappointment: book your spot by 17 September.
. |
|
|---|
| APPLICATIONS NOW OPEN FOR OUR DIGITAL PATHOLOGY AND AI EARLY DETECTION SANDPIT 18–20 November
Royal College of Pathologists
London Are you interested in how digital pathology and AI can improve turnaround times and diagnostic accuracy, and potentially pick up early signs of cancer? Our next sandpit with the Sciences and Technology Facilities Council will connect you with the experts from a range of disciplines to form novel collaborations that can transform the way we detect cancer. Successful teams will receive up to £100,000 in seed funding. Apply by 30 September. |
|
|---|
|
|---|
|
|
| | WESSELING GROUP: TWO NEW DCIS PAPERS Two new articles have emerged from the Grand Challenge PRECISION team, led by Jelle Wesseling, as part of their work to better understand ductal carcinoma in situ (DCIS): Their Trends in Cancer article outlines how to avoid overtreatment of DCIS patients through distinguishing harmless DCIS from that which is hazardous. Breast Cancer Research and Treatment published their cohort study on the reliability of preoperative breast biopsies showing DCIS and implications for non-operative treatment. |
|
|---|
|
|---|
|
|
PURSUE CANCER RESEARCH IN THE US Applications are open for the Fulbright-CRUK Scholar Awards. Open to academic and clinician researchers at postdoc level or above, the scheme allows you to undertake a 3-12 month research visit to the US. “It’s an amazing scheme. It supports you in preparation for travel, offers unique opportunities and events while in the US and the Fulbright network connects you with fellow scholars from all disciplines from across the world,” says Dr Stuart Williamson, a recent Fulbright Scholar. Deadline: 6 November 2019
. |
|
|---|
| THE IMPORTANCE OF RESEARCHER MOBILIITY “There are scientists from all over the world at my institute, working to accelerate progress in cancer research,” says Ines Figueiredo, originally from Portugal, who works as a Higher Scientific Officer at the Institute of Cancer Research. 50% of PhD students and 72% of postdocs we fund are not originally from the UK, and we want to ensure research staff can continue to travel easily to and from the UK post-Brexit. We’re sharing the stories of some of our researchers to explain why mobility matters to them and the role it plays in their work. |
|
|---|
|
|---|
|
|
| | MOLECULAR ANALYSIS FOR PERSONALISED THERAPY (MAP) 2019: SPOTLIGHT ON SPEAKERS This year’s three-day programme features sessions with some of the world’s leading scientists in precision medicine. Here’s just some of our most anticipated talks: Andrew Biankin (University of Glasgow) will be talking about novel therapeutic strategies to personalise treatment for pancreatic cancer patients. Samra Turajilic (The Institute of Cancer Research) will present on the clonal evolution of metastatic disease. Sergio Quezada (UCL) will discuss clonal diversity of T cells and how they react to the tumour microenvironment, immune co-inhibitory and co-stimulatory signals in lung cancer. |
|
|---|
|
|---|
|
|
CRUK AND HUMMINGBIRD BIOSCIENCE JOIN FORCES TO TRIAL NOVEL ANTI-HER3 ANTIBODY We have partnered with the biotechnology company Hummingbird Bioscience to undertake the early clinical development of Hummingbird’s anti-HER3 antibody HMBD-001. HMBD-001 is distinct from other anti-HER3 agents currently in development as it blocks all mechanisms through which HER3 can be activated. This overcomes an intrinsic mechanism that has prevented previous HER3 therapeutics from working effectively. Our Centre for Drug Development will fund the programme, manufacture the clinical grade antibody and conduct a phase I clinical trial. |
|
|---|
| INNOVATION SUMMIT 2019: TRANSLATING YOUR RESEARCH Our second Innovation Summit on 7 October at Alderley Park will explore the motives for, and benefits of, translating your research through an entrepreneurial approach. Hear from researchers that have embraced this approach who will discuss their journey and the support you can get from Cancer Research UK. Join us to build your supportive entrepreneurial network, and to engage personally with CRUK, our partners and local industry through 1-on-1 advice clinics.
. |
|
|---|
|
|---|
|
|
| | AN INSIGHT INTO THE DRUG DEVELOPMENT PROCESS: AZD0424 Only 1 or 2 compounds in every 10,000 tested actually makes it through to being used as a licensed treatment. So, what happens to the other 9,998 that fail the process? Many of these have valuable properties for use in research and discovery. Ximbio is the world’s largest non-profit dedicated to life science research reagents of all kinds, including the 9,998 that others may disregard. Discover the value of these compounds and how they could be used to help create future scientific breakthroughs. |
|
|---|
|
|---|
|
|
| | | EDINBURGH, UK 9 September 2019 |
|
|---|
|
|---|
| | | LONDON, UK 10-12 September 2019 |
|
|---|
|
|---|
| | | CALIFORNIA, USA 24-26 September 2019 |
|
|---|
|
|---|
| | | BART'S CANCER INSTITUTE, LONDON, UK 26 September 2019 |
|
|---|
|
|---|
| | | LONDON, UK 2-3 October 2019 |
|
|---|
|
|---|
| | | MANCHESTER, UK 7 October 2019 |
|
|---|
|
|---|
| | | KING'S COLLEGE LONDON, LONDON, UK 8 October 2019 |
|
|---|
|
|---|
| | | LONDON, UK 15-17 October 2019 |
|
|---|
|
|---|
| | | LONDON, UK 8-9 November 2019 |
|
|---|
|
|---|
| | | LONDON, UK 25 November 2019 |
|
|---|
|
|---|
|
|
| Been forwarded this email? Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
